Loss of heterozygosity (LOH) at specific loci may help localize tumor suppressor genes involved in the formation of various familial and sporadic tumors. In addition, the genetic loci for a number offamilial tumor syndromes have been mapped by linkage analysis. To explore the possible role of tumor suppressor genes in endocrine tumors, we tested 41 pheochromocytomas (34 sporadic and 7 familial) and 11 medullary thyroid cancers (MTC) (10 sporadic and 1 familial) for LOH near a variety of potentially important genetic loci: (a) the multiple endocrine neoplasia type 2A (MEN 2A) locus on chromosome 10; (b) the von Hippel-Lindau locus on 3p; and (c) the p53 and neurofibromatosis 1 loci on 17. We also examined chromosomes ip and 22q because previous studies in a small number of pheochromocytomas and MTCs suggested LOH in these regions. Background rates for LOH were assessed using several "random" probes. Finally, we examined a number of clinical and histologic characteristics of these tumors for possible correlations with specific genetic alterations. LOH in the region of the MEN 2A locus was uncommon (0% for MTCs, 5% for pheochromocytomas). However, we found significant allelic losses in pheochromocytomas on chromosomes ip (42%), 3p (16%), 17p (24%), and 22q (31%). We also noted a correlation between LOH on ip and urinary excretion of metanephrine by these patients (P = 0.02). LOH on ip, 3p, and 17p also appeared to be associated with increased tumor volume. Analysis of the smaller number of MTCs demonstrated allelic losses on chromosomes lp and 22q. Our results suggest that tumor formation and/or progression in pheochromocytomas and MTCs involves multiple genes, analogous with the model proposed for colon carcinoma. (J. Clin. Invest. 1991. 87:1691-1699
Introduction
The inactivation of tumor suppressor genes is thought to be important in the pathogenesis ofmany human cancers (1) . The prototypic model for tumor suppressor genes is the retinoblas-toma (RB 1)' gene, which has been cloned and sequenced (2) . Retinoblastoma can occur either in a hereditary or a sporadic form. In the hereditary form of the disease, one RB1 allele is abnormal in the germ line and the second allele is inactivated as a somatic event. In the sporadic form, both RB 1 alleles are inactivated in somatic cells, leading to tumor formation (3) . Thus, similar genetic mechanisms are involved in both forms of the disease, with tumors occurring at a far higher frequency in the familial form since fewer somatic mutations are required for tumor formation (3) .
In contrast to the RB 1 gene, the sequences of other tumor suppressor genes are unknown. The chromosomal locations of candidate tumor suppressor genes are inferred, however, based on the detection of somatic allelic losses in various tumors. Combined with linkage analysis, such an approach has led to the localization of several cancer-predisposing genes, such as the genes for multiple endocrine neoplasia type 1 (MEN 1) (4), MEN 2A (5, 6) , neurofibromatosis 2 (NF 2) (7), von HippelLindau disease (VHL) (8) , and familial adenomatous polyposis (FAP) of the colon (9, 10) .
Like retinoblastoma, pheochromocytoma and medullary thyroid carcinoma (MTC) can occur in both familial and sporadic forms. Both are components of the MEN 2A syndrome, which has been mapped to the centromeric region on chromosome 10 (5, 6) . In contrast to retinoblastoma, however, allelic loss on chromosome 10 near the MEN 2A locus has been an uncommon event in these tumors (11, 12) . This has led to speculation that the MEN 2A gene may not be entirely analogous to the RBl gene (12). In retinoblastoma, the inherited mutation in familial cases is typically a small deletion or, presumably, a point mutation. The loss of the second allele in a tumor cell, in contrast, often involves loss of a large piece of DNA, detectable by a loss of heterozygosity (LOH) analysis. In this model, it appears that both copies ofthe RB1 gene need to be inactivated for phenotypic effects (1, 3) . In contrast to retinoblastoma, in other familial cancer syndromes phenotypic effects could result from the loss or inactivation ofonly one copy of the putative tumor suppressor gene (1) . Indeed, this appears to be the case for FAP, which has been mapped to chromosome Sq (9, 10) . In that syndrome, generalized colonic epithelial hyperplasia occurs without loss of the wild-type allele, presumably reflecting a gene dosage effect of the FAP gene (13) . In FAP, genetic changes at other loci involving chromosomes 12p, 18q, and 17p, and possibly others, are then thought to contribute to the transition to malignancy (13 In these studies, we tested the above prediction by examining a large number of pheochromocytomas and MTCs for allelic losses at several potentially important genetic loci. In addition to the MEN 2A locus on chromosome 10, we also examined chromosomes lp and 22q because previous studies in a small number of tumors had suggested LOH for various markers in these regions (14) (15) (16) . Since pheochromocytomas are also found in VHL disease and NF 1, we also tested the pheochromocytomas for LOH on chromosomes 3p and 17, where the genes for these syndromes have been ntapped or, in the case of NF 1, recently cloned (8, 17, 18) . Our results support the hypothesis that multiple genetic alterations on chromosomes lp, 22q, 17p, and 3p may be involved in the development of pheochromocytomas. Based on a clinical analysis of the pheochromocytomas, our studies further suggest a relationship between specific genetic changes and certain clinical characteristics of the tumors.
Methods
Clinical material. Tumors and peripheral blood leukocyte DNA were analyzed from 41 patients with pheochromocytoma and I I with MTC. locus was considered informative for a particular patient when the constitutional DNA from that patient displayed two different alleles (i.e., heterozygosity at that locus). LOH was scored only if there was absence or marked reduction in the intensity of one of the two allele bands (Fig. 1 ). In addition, visually assessed allele loss was confirmed by scanning densitometry. For all ofthe two allele probes, the residual absorbance ofthe deleted band in tumor DNA was normalized against the absorbance of the retained band in order to adjust for DNA content. The band in constitutional DNA corresponding to the deleted band in tumor DNA was similarly normalized. The normalized intensity ofthe deleted band in tumor DNA was then divided by the normalized intensity ofthe corresponding band in constitutional DNA to obtain a relative intensity value. As shown in Fig. 2 (Fig. 1  a) (34, 35) . As noted by Genuardi et al. (34) in their analysis of breast cancers with the p1-79 probe, the banding pattern in constitutional DNA consists of a combination of bands. Some bands are unique to each of the two chromosomes whereas others are common to both chromosomes. With allelic loss, one typically sees loss of bands which are specific for the deleted chromosome. In addition, bands which are common to both chromosomes are reduced in intensity by 50%. Finally, bands unique to the retained chromosome remain unchanged in intensity. This is illustrated in Fig. 3 a, which is a densitometric scan of the p1-79 (Taq 1) blot shown in Fig. 1 a. As is evident, band D, which corresponds to the arrow in Fig. 1 a, is deleted in tumor DNA. In addition, relative to band A, multiple other bands are reduced in intensity. Band A thus represents a band unique to the retained chromosome, whereas bands B and C represent bands common to both chromosomes. Band D, in contrast, is unique to the deleted chromosome and absent in tumor DNA. When the intensities of bands B and C are normalized against band A in tumor and normal DNA and the relative intensity values calculated, it is clear that bands B and Care reduced in intensity by -50%. Fig. 3 b shows the corresponding densitometric plots from a tumor scored visually as negative. In this scan, every peak in normal DNA has a corresponding peak in tumor DNA with the relative intensities of all peaks remaining the same. We therefore confirmed allelic loss in all our positive tumors by performing densitometric scans on the autoradiograms and demonstrating each ofthe following: (a) the presence of retained bands relative to which numerous other bands were reduced in intensity; (b) the presence of unequivocally deleted bands with residual relative intensity values of< 30%; and (c) the presence of common bands which were reduced in relative intensity by 50%. This is summarized in Fig. 2 b which also indicates that such an analysis on a sample oftumors scored visually as negative gave relative intensity values of any given band in tumor DNA of -1.0. N-myc gene amplification. We performed analysis for possible Nmyc gene amplification with the N-myc probe pNB-l, using the restriction endonuclease EcoRI (36) . The membranes were concomitantly hybridized with a known single copy marker, KM. 19 (locus D7S23, 7q3 I -q32) (37) . The signal for pNB-l was normalized against that for Nuclear DNA ploidy status. The study material consisted of paraffin-embedded tissue blocks of the pheochromocytomas. Hematoxylin and eosin stained slides were made of 6-1sM thick sections from the front and back of each pheochromocytoma block analyzed. These slides were all examined by a pathologist to ensure the presence of tumor tissue in the 40-,sM thick sections used for analysis of DNA content. Nuclear suspensions were prepared for the paraffin-embedded tissue blocks and the isolated nuclei stained with propidium iodide by standard methods (38) . Nuclear mor, familial versus sporadic tumor, tumor volume, nuclear ploidy status, preoperative plasma calcitonin level (MTC), or preoperative urine metanephrine (pheochromocytomas). Statistical methods. The incidence of allelic loss was calculated by dividing the number oftumors demonstrating loss by the total number of tumors informative with a particular probe. Where more than one probe was used in a given chromosomal region, an aggregate percentage was calculated. For this, the number oftumors demonstrating loss with either probe was divided by the total number informative with either probe. For our data, we judged an incidence of 3% to be the highest anticipated incidence of background loss (see below and Table  III) . For each probe/enzyme combination, we report P values, computed by the binomial distribution, testing whether the observed incidence was significantly greater than a background loss of 3%. We also report 95% confidence intervals to demonstrate the range ofpercentage allelic loss which is consistent with our data.
The only patients with sporadic pheochromocytomas. The patient with familial MTC was also uninformative with both probes. Other allelic losses: pheochromocytomas. The region of most dramatic allelic loss in the pheochromocytomas was on chromosome 1 p (Table III) . Overall, 13 of 31 informative pheochromocytomas (42%) demonstrated LOH on the distal portion of I p. For comparative purposes, the RB I locus on 1 3q as well as several random probes on 2p, 5q, and 16p were used to provide a "background" rate ofallelic losses in pheochromocytomas. Pheochromocytomas tended to be chromosomally stable, with our highest background rate being 3% on 2p. When compared with this background rate of 3%, the 42% loss noted on lp was highly statistically significant (P < 0.001). Fig. 1 a shows representative blots demonstrating allelic losses with the lp probes AF3 and p 1-79. As noted earlier, probe p 1-79 provided a fingerprint pattern with 20-40 bands. The high interindividual variability of this probe is related to the presence of different copy numbers of a core sequence spanning 39-40 bp (21) . LOH with the probe is scored as positive when one or more bands are deleted in tumor DNA (Fig. 1  a and references [34 and 35] ). Because the banding pattern may be difficult to interpret, a tumor was scored as positive for LOH only if it demonstrated LOH after digestion with two restriction endonucleases, PstI and TaqI. In addition, since even a small amount of DNA degradation makes the banding pattern difficult to interpret, any tumor where this was noted was scored as uninformative. As a control, and to eliminate the possibility of technical artifact, 20 colon carcinomas and 10 osteogenic sarcomas were concomitantly analyzed with p and none demonstrated LOH (data not shown). Finally, as noted earlier, we performed a detailed densitometric analysis on all tumors scored visually as positive and demonstrated the presence of clearly deleted bands as well as other bands which were reduced in intensity by 50% (Figs. 2 b and 3) . Of the tumors positive for LOH on 1 p, one tumor was positive with the more distal pl-79 probe (1p36.3) but negative with the more proximal AF3 probe (lp34-35). In contrast to studies with neuroblastomas demonstrating a correlation between LOH on lp and N-myc gene amplification (35) , none of our pheochromocytomas demonstrated amplification of N-myc (data not shown).
In addition to lp, pheochromocytomas also demonstrated significant LOH on 22q, 3p and 17p (Table III, Fig. 1) . None of the 12 informative pheochromocytomas had LOH at the RB1 locus, arguing against a role for the retinoblastoma gene in pheochromocytoma formation. Our patient with VHL and pheochromocytoma had no LOH at 3p. Both our NF 1 patients were also negative for LOH on 17p. We analyzed the pheochromocytomas for LOH on 17p even though the NF 1 gene lies on 1 7q 1 1.2 (17, 18) , because LOH in NF 1 associated tumors may occur principally on 1 7p (17) . Furthermore, the p53 gene, which is involved in colorectal cancer and possibly several other tumors (40) , lies on 17p1 3.1. We did, however, examine the 7 sporadic pheochromocytomas that demonstrated LOH on 1 7p (Table III) for LOH on 1 7q with the probe pTHH59 (17q23-q25.3). Of the 7 tumors, 3 were negative, 3
were uninformative, and only 1 demonstrated LOH for the 1 7q marker.
In Table V , we compare rates of allelic losses in sporadic versus familial pheochromocytomas. As is evident, while the number of familial tumors was relatively small, there appeared to be no differences in the overall rates of allelic losses. Thus, while pheochromocytomas showed no significant LOH on chromosome 10 near the MEN 2A locus, there was frequent and statistically significant LOH on chromosomes lp, 3p, 17p, and 22q (Fig. 4) .
Other allelic losses: MTCs. Table IV shows the data for allelic losses in MTCs. In parallel with the pheochromocytoma data, none of 7 informative MTCs showed LOH in the region ofthe MEN 2A locus. 1 of 11 MTCs (9%) showed loss on Ip, a value statistically different from the highest background rate of 3%, but the 95% confidence intervals included 3%. Similarly, 2 of 10 tumors (20%) showed loss on 22q (P < 0.05). No LOH was noted on chromosomes 3p, 17p, 13q, 2p, 5q, or 16p. Taken together with the pheochromocytoma data, the above numbers suggest a potential role for genes on lp and 22q in MTC development.
Clinical correlations. To define whether the observed genetic changes in the tumors were functionally important, we compared demographic and clinical characteristics of patients with and without allelic losses on lp, 3p, 17p, and 22q. Specifically, we examined whether patient sex, age, benignancy versus malignancy, familial or sporadic tumor, tumor volume, nuclear ploidy status, preoperative urine metanephrine excretion (pheochromocytomas), or preoperative calcitonin level (MTC) were associated with allelic loss in any ofthe above regions. No such correlations were noted for the MTCs. For the pheochromocytomas, however, increased tumor volume appeared to be associated with LOH on chromosome lp (155±46 cm3 [mean±SE] for those with loss vs. 68±19cm3 for those without; P = 0.08) as well as 3p (299±105 cm3 vs. 88+20 cm3; P = 0.04) and possibly 17p (172±69 cm3 vs. 100±30 cm3; P = 0.16) (Fig.   5 a) . While only one ofthe above correlations achieved statistical significance, the trend in all three instances was clearly in the same direction. In addition, urinary metanephrine excretion was significantly greater in tumors demonstrating LOH on lp (8.5±2.3 mg/24 h vs. 2.8±0.5 mg/24 h; P = 0.02) (Fig. 5 b) . Thus, tumors with LOH on lp tended to be larger and secreted significantly greater amounts of catecholamines than tumors without LOH on lp. LOH on 3p and possibly 17p also appeared to be correlated with larger tumor volume. No such correlations were noted for LOH on 22q. None of the other parameters examined in the pheochromocytomas showed any correlation with LOH in any of the above regions.
Discussion
While the retinoblastoma paradigm is an attractive model for tumorigenesis, it has become clear that not all familial cancer syndromes will follow such a straightforward pattern. FAP and colon carcinoma provide the best alternative model to date in which multiple genes appear to be involved in tumor formation and/or progression (13) . With study and two previous ones show conclusively that this is not the case (1 1, 12 ). In analogy with FAP, Nelkin et al. proposed that in familial pheochromocytomas and MTCs, the inherited abnormality on chromosome 10 may predispose to hyperplasia with subsequent changes on other chromosomes contributing to the transformation to pheochromocytoma or MTC (12). Indeed, C cell and adrenomedullary hyperplasia is a well established premalignant lesion in familial pheochromocytoma and MTC, and may represent the phenotypic consequence of the germ line mutation in the MEN 2A gene (41, 42) . Ifthe above model is correct, then one would expect to find other genetic alterations in pheochromocytomas and MTCs that may contribute to tumor formation and/or progression. Because of the scarcity of these tumors, it has been difficult to perform an allelic loss study on these tumors that would have statistical validity. Mathew et al., for example, noted LOH on lp in four ofsix pheochromocytomas and three ofeight MTCs (14) . In a more recent study, Yang et al. published data on one pheochromocytoma and seven MTCs, with five of their eight tumors demonstrating allelic loss on lp (15). Mathew et al. did examine background rates of allelic loss, but because of the small numbers, no formal statistical analysis was possible.
We present here data on a large number ofpheochromocytomas demonstrating statistically significant LOH on lp, 3p, 1 7p, and 22q. These data thus provide support for the multistep model oftumorigenesis proposed by Nelkin for MEN 2-associated tumors. We further demonstrate that LOH on lp is associated with a clinically important tumor marker, namely urinary metanephrine excretion. In addition, LOH on lp, 3p, and 1 7p was associated with increased tumor volume, although the relationship was statistically significant only for 3p. The above data suggests that the genetic changes are not random inconsequential events, but rather potentially involved in tumor formation and/or progression. The fact that chromosome lp and 3p changes were present predominantly in larger tumors suggests that these particular changes may in fact be more important in tumor progression rather than formation. The issue of the specific order in which the genetic changes described in these tumors might occur is beyond the scope of these studies.
Of note, each of the chromosomal regions where we noted LOH has been shown in other studies to harbor a potential tumor suppressor gene. In addition to pheochromocytomas and MTCs, LOH on I p has been noted in neuroblastomas (35) , breast cancer (34) , and familial melanoma (43 (44) . Interestingly, the gene for NF 2, which leads to familial acoustic neuromas and meningiomas, has been mapped by linkage analysis to the same region ofchromosome 22 that appears to be lost in the above tumors (6) .
Chromosome 1 7p deletions have most commonly been associated with colorectal cancer and there is strong evidence for involvement ofthe p53 gene on 17p 13-1 in the pathogenesis of colon carcinomas (13) . Allelic loss and point mutations involving the p53 gene have also been demonstrated for a variety of tumors including brain, breast, lung, and in a neurofibrosarcoma from a patient with NF 1 (40) . In this study, 7 of 29 pheochromocytomas (24%) demonstrated LOH on 17p. Further evidence for involvement ofthe p53 gene in the pathogenesis of pheochromocytomas would come from direct sequence analysis of the p53 gene, particularly in the 7 tumors demonstrating allelic losses on 17p. These studies are currently in progress.
Chromosome 3p deletions have been described in renal cell carcinomas (45) as well as lung carcinomas (46) . In addition, the gene for VHL, which leads to inherited retinal angiomas, cerebellar hemangioblastomas, renal carcinomas, and pheochromocytomas, has been mapped to the distal portion of 3p by linkage analysis (8) . Our studies suggest that some sporadic pheochromocytomas do harbor allelic losses in the region of this presumed tumor suppressor gene.
While the presence ofallelic losses on chromosome 1 p, 22q, 1 7p, and 3p suggest a mechanism involving loss oftumor suppressor genes, several alternative interpretations are also possible. As Mathew et al. have suggested for chromosome 1 (14) , it is possible that mutations in oncogenes on one of the above chromosomes followed by loss of the corresponding wild-type alleles may then lead to cooperation between the mutant oncogenes and the MEN 2 gene. While not providing mechanistic explanations, our findings do suggest potential chromosomal regions that may harbor genes important in pheochromocytoma development.
The statistical validity of our analysis depends to some degree on how accurately we succeeded in assessing background rates of loss in these tumors. In (Tables III and IV) .
In summary, these studies provide evidence for significant LOH in pheochromocytomas on chromosome lp, 22q, 17p, and 3p. Combined with the lack of allelic loss near the MEN 2A locus, these data provide further support for the hypothesis that tumongenesis in MEN 2A-associated tumors may follow a more complex pathway than the simple retinoblastoma paradigm. Our data do not exclude the involvement of other, as yet undefined, genetic alterations that may contribute to tumor formation. These studies do, however, provide important clues for future studies aimed at a more precise elucidation of the genetic changes in these tumors.
